Novartis announced that the European Commission (EC) has approved its Cosentyx® (secukinumab) for a new indication to treat active moderate to severe hidradenitis suppurativa (HS) in adult patients who have had an inadequate response to conventional systemic HS therapy. This is the first biologic treatment approved for HS in nearly a decade. Novartis said a decision from the FDA for this indication is expected later this year.
This approval follows the CHMP recommendation last month.
Print Page Mail Article